comprehensive -WSS

comprehensive

author：knowledge 2025-10-02 00:28:46 - browse：172

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： FogPharma raises $145 million in rare Series E round

focus

hotspot

knowledge

WSS

An inside look at PIPEs, biotech's buzzy new financing tool

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

One Duchenne patient's bittersweet hope for new treatment

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Flu vaccine offering decent levels of protection this winter, new data show

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

explore

comprehensive

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

A Greenpeace activist is fined for crash

Bright Health sells Medicare Advantage business to Molina

A Greenpeace activist is fined for crash

How to save PrEP access — and even expand it

How to fix the rural physician shortage in the U.S.

Continuity nursing helped my family in our darkest PICU moments

Kenai launches with $82 million for Parkinson’s stem cell therapy

State Dept. review finds Biden bears some blame for Afghanistan failures

House looks to weaken Medicare negotiation

hotspot

The debate over Covid

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

RSV vaccines may be linked to small increased risk of developing GBS

RaDonda Vaught to speak at CommonSpirit event on patient safety

Change Healthcare cyberattack outage could last weeks

Antibody drugs appear effective. Now can we make enough of them?

focus

hotspot

knowledge

hotspot